Brief: Mustang Bio And City Of Hope Announce First Patient Dosed In Phase 1 Clinical Trial Of MB-101
18/05/2021 13:44
May 18 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO AND CITY OF HOPE ANNOUNCE FIRST PATIENT DOSED
IN
PHASE 1 CLINICAL TRIAL OF MB-101 (IL13RΑ2-SPECIFIC CAR T CELLS)
TO TREAT LEPTOMENINGEAL BRAIN TUMORS
Source text for Eikon: ID:nGNX1JzBGQ
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie